Icecure Medical is trading at $1.46, down -5.19%; no clear catalyst for the decline was identified. - On October 6, IceCure announced Legacy Health in Portland joined its FDA-approved ChoICE post-market study. - The study is expected to enroll about 400 patients across up to 30 U.S. sites. Available reporting does not link the positive study expansion news to the share-price decline. - The broader market is higher, which does not explain the stock’s opposite-direction move; trading-volume information was unavailable.